2013, Number 10
Clinic characteristics of patients with trophoblastic gestational disease complicate with hypertension
PDF size: 152.95 Kb.
ABSTRACTBackground: The polycystic ovary syndrome (PCOS) it is a metabolic disorder with insulin resistance associated. Have been recently described contributor factors in the presence of insulin resistance that need to be studied. These factors can be the nutrients in the daily diet, final products of the advanced glycated end-products (AGEs), reactive derivatives of non enzymatic glucose-protein reactions either produced endogenously or ingested from dietary sources. The aim was to modifies the food intake to know the contribution on improve insulin resistance.
Objective: Compare different diets and changes in insulin resistance in patients with polycystic ovary syndrome.
Material and methods: As longitudinal, prospective and descriptive study, were included women with age among 18 to 40 years who received a compound with amino acids, extracts and anti-oxidants to dose of 660mg every 8 hours for 6 months. The inclusion approaches included the insulin resistance presence HOMA-IR › 2.6, elevated LH, and presence of ovaries with cysts by ultrasound. Statistical analysis with ANOVA one way to p ‹ 0.05.
Results: Were included a total of 30 patients, of which 28 patients had improvement in the insulin resistance from the 3 months, but until the 6 months they had significant difference (p ‹0.05), compared with 24 women from control group.
With this result is demonstrated that it is necessary to modify the diet and to offer alimentary support to avoid the oxidative stress that takes impairment the insulin signaling with the subsequent insulin resistance.
Ehrmann DA. Polycystic ovary syndrome. N Engl Med 2005;352:1223-1236.
Zárate A, Morán C, Hernández-Valencia M, Saucedo R. Criterio actual para el diagnóstico del síndrome de ovario poliquístico. Ginecol Obstet Mex 2004;72:283-288.
Zegher F, Ibañez L. Early origins of polycystic ovary syndrome: hypothesis may change without notice. J Clin Endocrinol Metab 2009;94:3682-3685.
Morán C, Hernández-Valencia M, Cravioto MC, Porias HL, Malacara JM, Bermúdez JA. Síndrome de ovario poliquístico. Posición de la Sociedad Mexicana de Nutrición y Endocrinología. Rev Endo Nutrición 2006;14:7-12.
Apridonidze T, Essah PA, Iourno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:1929-1935.
Pascuali R, Stener VE, Yildiz BO, Duleba AJ, Legro RS. PCOS forum: research in polycystic ovary syndrome today and tomorrow. Clin Endocrinol 2011;74:424-433.
Ketel IJG, Stehouwer CDA, Serne EH, Korsen TJM, Hompes PGA, Smulders YM, Jongh RT, Homburg R, Lambalk CB. Obese but not normal-weight women with polycystic ovary syndrome are characterized by metabolic and microvascular insulin resistance. J Clin Endocrinol Metab 2008;93:626-629.
Diamanti-Kandarakis E, Katsikis I, Piperi C. Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS). Clin Endocrinol 2008;69:634-641.
Diamanti-Kandarakis E, Katsikis I, Piperi C. Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome. Clin Endocrinol 2007;66:103-109.
Hernández-Valencia M. Repercusión de las alteraciones en los mecanismos de señalización del receptor de insulina. Rev Med Inst Mex Seguro Soc 2006;44:383-388.
Siegel S, Fulterweit W, Davies TF, Concepcion ES, Greenberg DA, Villanueva R, Torner Y. A c/t single nucleotide polymorphism at the tyrosine kinase domain of the insulin receptor gene is associated with polycystic ovary syndrome. Fertil Steril 2002;78:1240-1243.
Hernández-Valencia M, Zárate A, Sandoval A, Ruiz M, Timossi C, Amato C, Basurto L. Conjugated estrogens and tibolone modify the gonadotrophin glycosylation pattern in postmenopausal women. Ginecol Obstet Invest 2006;63:22-27.
Diamanti-Kandarakis E, Piperi C, Patsouris E. Immunohistochemical localization of advanced glycation end products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries. Histochem Cell Biol 2007;127:581- 589.
Hernández-Yero JA, Vargas GD. Utility of Diamel in patients with type 2 diabetes mellitus receiving combination therapy with glibenclamide. Diabetologia 2006;23:284- 290.
Zárate A, Saucedo R, Hernández-Valencia M. Metformin en el tratamiento del síndrome de ovarios poliquísticos (síndrome de Stein-Leventhal). Acta Med G A 2005;3:51- 52.
Hernández-Valencia M, Hernández Rosas M, Zárate A. Atención de la resistencia a la insulina en el síndrome de ovarios poliquísticos. Ginecol Obstet Mex 2010;78:612- 616.